15 April 2020

Royal Papworth Hospital has now recruited its 50th coronavirus patient to the national RECOVERY Trial.

The trial is attempting to identify treatments that might be beneficial for adults who have been hospitalised with COVID-19.

Led by the University of Oxford, there are now more than 4,500 patients taking part in the trial from more than 160 hospitals.

A range of potential treatments that already exist for other conditions have been suggested for COVID-19, but as yet it is not known if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive.

Some of these treatments that the RECOVERY Trial will begin testing are:

  • Standard of care.
  • Lopinavir-Ritonavir (anti-viral treatment more commonly used to treat HIV).
  • Low-dose Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation).
  • Hydroxychloroquine (related to an anti-malarial drug).
  • Azithromycin (an antibiotic).

Dr Robert Rintoul, Principal Investigator for RECOVERY at Royal Papworth Hospital, said: “To recruit 50 patients here at Royal Papworth Hospital is a fantastic effort by our research and development team, who have been working closely with critical care and ward staff.

“I also want to say thank you to all the patients and their families for their support by taking part in RECOVERY.”

This trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome,  the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.


Our charitable appeal is aiming to raise vital funds for staff support, research, and patient welfare. Find out more about The Royal Papworth Hospital COVID-19 Appeal